Commentary

0
0
0
s2sdefault

Karl Fagerstrom | 14 December 2013

We used to believe that nicotine is very dependence producing, but the evidence suggests that there are a number of problems with this statement. For example, animals do not self-administer nicotine as readily as they do other dependence producing drugs such as amphetamine, cocaine, and heroin (Villegier et al. 2003); nicotine is a relatively weak reinforcer in human laboratory studies (Perkins et al. 2001); abstinent smokers seem to prefer a much reduced or nicotine free e-cigarette rather than other - often stronger - nicotine-containing products like gum; and although nicotine replacement treatment is an effective aid for quitting smoking, its efficacy is moderate even in doses that replace most or all nicotine from the cigarettes formerly used (Dale et al. 1995). There is very little to no evidence for the abuse of nicotine when not delivered in a tobacco vehicle.

0
0
0
s2sdefault

Gilbert Ross | 8 December 2013

Smoking is a leading cause of death, and cessation treatments are largely ineffective, yet regulation threatens a promising new technology that might help smokers quit. 

Anyone with a modicum of knowledge regarding public health will agree that the most important, devastating, and preventable issue facing America is the human toll of cigarettes.

 

0
0
0
s2sdefault

Jon Spring | 1 December 2013

All quotes attributed in the following piece are from the transcripts of the E-Cigarette Summit, held at the Royal Society in London, on November 12, 2013 [i] The Summit provided a vital and timely meeting for scientists, policymakers, public health professionals and e-cigarette stakeholders to come together and debate the future of e-cigarettes in context of health, efficacy and regulation.

0
0
0
s2sdefault

Gerry Stimson | 25 November 2013

The European Parliament voted on October 8th voted to reject medicines regulation for e-cigarettes. Instead it passed Amendment 170 which sought to regulate e-cigarettes as consumer products. The main elements of this amendment were that medicines legislation would apply to products where a health claim is made i.e. that the product can be used for treating or preventing disease.

0
0
0
s2sdefault

Lars Ramström | 25 November 2013

The revision of the EU Tobacco Products Directive raises some interesting issues regarding smokeless tobacco products (STP). In the Directive those oral STPs that are kept in the mouth (Swedish snus) are called ‘oral tobacco’, while those oral STPs that are chewed in the mouth are called ‘other STP’.

0
0
0
s2sdefault

Mirosław Dworniczak | 17 November 2013

From time to time e-cigarettes appear in the media. Unfortunately, they are usually still presented in a bad light. The usual arguments are as follows: we do not know exactly what's inside an e-cigarette, they are as poisonous as „the real ones”, there's no research concerning e-cigarettes. 

0
0
0
s2sdefault

Clive Bates | 17 November 2013

The investment analysts are always interesting on tobacco and e-cigs, and in a usefully dispassionate ‘follow-the-money’ kind of way.

Here’s a small collection of quotes I’ve seen in recent analyst reports mainly as they relate to regulation of e-cigarettes. I don’t see all reports of course so this is necessarily selective.

0
0
0
s2sdefault

Marcel Göertz | 10 November 2013

A couple of months ago, e-cigarette users from the Dutch speaking part of Belgium and the Netherlands joined hands and formed a group of activist vapers. Acvoda - Actie Comité voor Dampers (Action Committee for Vapers) - was born. While this seems a logical unison, the fact is that the current situation for Dutch e-cigarette users is completely different than the situation for the Belgian users.

0
0
0
s2sdefault

Suzi Gage | 02 November 2013

The tobacco industry has been shown to mislead with its research, but is forcing it to become more hidden a better option? Last week, the BMJ announced that it was finally implementing a practice that it had been discussing since the mid 1990s. Research partly or fully funded by the tobacco industry will no longer be published in BMJ, BMJ Open, Thorax and Heart. 

0
0
0
s2sdefault

Clive Bates | 16 October 2013

On 8th October in Strasbourg, the European Parliament voted on a raft of measures to regulate tobacco and nicotine products. The headlines were the following [also see Telegraph summary]:

  • a ban on menthol and other flavoured cigarettes from 2022
  • warnings covering 65% of packs (30% now – campaigners are pushing for 75% and the right to go further)
  • a ban on selling cigarettes in packs of less than 20
  • no ban on ‘slim’ cigarettes
  • a ban on most additives in tobacco products
  • a continuation of the ban on snus outside Sweden in the face of all evidence.